L’Oréal Groupe to acquire majority stake in Medik8 expanding science-backed skincare offer

L’Oréal Groupe has signed an agreement to acquire a majority stake in British premium skincare brand Medik8, strengthening its L’Oréal Luxe portfolio in the science-led skincare category. Medik8 Founder Elliot Isaacs will continue to serve on the board alongside the current management committee to ensure continuity.

Inflexion, the European private equity firm that invested in Medik8 in 2021, will retain a minority interest in the business.

Known for its science-backed formulations, flagship product Crystal Retinal serum and its CSA Philosophy – Vitamin C and sunscreen by day, Vitamin A by night – Medik8 has gained traction across professional and consumer skincare markets.

Medik8 has an established omnichannel distribution model with a strong footprint across leading online and offline retail platforms in Europe and an expanding presence in the USA.

L’Oréal Luxe President Cyril Chapuy commented, “We are delighted to welcome Medik8 to the L’Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio. We share a strong belief in Medik8’s global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.”

“This is an exciting day for Medik8,” added Medik8 CEO Simon Coble. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8’s journey, as we work together to bring our innovative products to a wider audience.”

The Group will begin consolidating Medik8’s sales from the closing date of the transaction, expected in the coming months, subject to regulatory approvals and standard closing conditions. The agreement includes a provision for L’Oréal to acquire the remaining minority shares in the future.